Immatics Announces Full Year 2023 Financial Results and Corporate Update
March 21, 2024 07:00 ET
|
https://immatics.com/
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median...
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024 16:05 ET
|
Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 12, 2024 16:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Regenerative Medicine Industry Analysis and Outlook 2024-2034: Oncology Applications Lead the Forecasted $168 Billion Global Market
March 11, 2024 13:40 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Market Analysis & Forecast to 2024-2034: Market By Product; By Application; By End-user; and By Region" report has...
Cell Therapy Market Insights Report: Collaboration and Licensing Deals 2016-2023
March 11, 2024 13:31 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Cell Therapy Collaboration and...
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
March 07, 2024 16:00 ET
|
Neurona Therapeutics
Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements
March 06, 2024 06:55 ET
|
ANTION BIOSCIENCES SA
Antion Biosciences release in vivo proof-of-concept data for miCAR7 and milestone achievement for Allogene Therapeutics
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
March 05, 2024 16:30 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
February 29, 2024 16:01 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, MA.
Gracell Biotechnologies Acquisition Completed
February 22, 2024 08:45 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical...